Yoon H. Park

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Remote-Controllable Immune-Priming Spot Formation Via Nanocomplexed Hydrogel-Assisted Histotripsy: Immunoasis.

Remote-Controllable Immune-Priming Spot Formation Via Nanocomplexed Hydrogel-Assisted Histotripsy: Immunoasis.

Journal: Advanced materials (Deerfield Beach, Fla.)
Published: September 16, 2025

Erratum to: Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2.

Erratum to: Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2.

Journal: BMB reports
Published: August 25, 2025

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma.

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma.

Journal: Blood
Published: September 30, 2024

Comprehensive immune cell spectral library for large-scale human primary T, B, and NK cell proteomics.

Comprehensive immune cell spectral library for large-scale human primary T, B, and NK cell proteomics.

Journal: Scientific data
Published: March 27, 2024

The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma.

The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma.

Journal: Blood
Published: October 25, 2022

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.

Journal: Cancers
Published: October 08, 2022

Enhancing adoptive T-cell therapy with fucoidan-based IL-2 delivery microcapsules.

Enhancing adoptive T-cell therapy with fucoidan-based IL-2 delivery microcapsules.

Journal: Bioengineering & translational medicine
Published: March 10, 2022

PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.

PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.

Journal: Biomedicines
Published: December 15, 2021

Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy.

Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: September 29, 2021

Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.

Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.

Journal: Biomaterials
Published: January 10, 2021

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.

Journal: BMB reports
Published: October 06, 2020

Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines.

Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines.

Journal: Annals of surgical treatment and research
Published: September 09, 2019
Showing 1-12 of 16

Last Updated: 09/26/2026